Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?

Affiliations


Abstract

Disease-modifying therapies (DMTs) delay or may prevent the progression of patients with high-risk clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (MS), and from relapsing-remitting MS to secondary progressive MS. Current evidence on the effects of DMT on disability in MS is supported by the use of the Expanded Disability Status Scale (EDSS), which is dominated by ambulation, and usually used as a secondary outcome measure. Less is known about the long-term effects of DMTs on other aspects of functional status, particularly cognition, which is a key determinant of ability to work. The time scale for measurements of disability is at most a few years, with scant data from more than 10 years of observation. Longer prospective follow-up of large numbers of patients with CIS is needed to determine whether early intervention with a DMT influences long-term disease progression. Finally, the emergence of the radiologically isolated syndrome (RIS) as a clinical entity has shifted the debate about when to intervene to an even earlier time frame. Balancing the significant side-effects associated with DMT in general and the expected outcome of pharmacologic intervention is increasingly problematic for managing patients with uncertain prognosis, as many patients may have low-risk CIS, benign MS or patients with RIS only. Preventing long-term disability in MS should be recognised more clearly as an important outcome in its own right, with disability measured more consistently with more sensitive instruments beyond the use of the EDSS.

Keywords: Multiple sclerosis; clinical isolated syndrome; disability; disease-modifying therapy; radiologically isolated syndrome.


Cited by

Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.

Celius EG, Thompson H, Pontaga M, Langdon D, Laroni A, Potra S, Bharadia T, Yeandle D, Shanahan J, van Galen P, Alexandri N, Kesselring J.Patient Prefer Adherence. 2021 Jan 8;15:15-27. doi: 10.2147/PPA.S268829. eCollection 2021.PMID: 33447018 Free PMC article. Review.

Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System.

De Luca C, Colangelo AM, Alberghina L, Papa M.Front Cell Neurosci. 2018 Nov 26;12:459. doi: 10.3389/fncel.2018.00459. eCollection 2018.PMID: 30534057 Free PMC article. Review.

Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases.

De Luca C, Virtuoso A, Maggio N, Papa M.Int J Mol Sci. 2017 Oct 12;18(10):2128. doi: 10.3390/ijms18102128.PMID: 29023416 Free PMC article. Review.


References

https://pubmed.ncbi.nlm.nih.gov/